Orexo AB ( (ORXOF) ) has released its Q4 earnings. Here is a breakdown of the information Orexo AB presented to its investors.
Orexo AB, a pharmaceutical company focused on opioid dependence and drug delivery technology, reported its fourth-quarter and full-year 2024 financial results, highlighting key financial performance and strategic developments. Despite a slight decline in total net revenues to SEK 160.3 million for Q4 2024 compared to the previous year, the company achieved an EBITDA of SEK 28.9 million, demonstrating improved operational efficiency. Significant impairments related to digital health products Deprexis and Vorvida impacted net earnings, resulting in a net loss of SEK -116.2 million for the quarter. However, Orexo’s US Commercial segment showed stable revenue performance, particularly from its Zubsolv product, contributing to a positive EBITDA for the year. Strategic highlights included the settlement of patent litigation concerning Zubsolv with Sun Pharmaceutical Industries and a new collaboration with Abera Bioscience on nasal powder vaccines. The company’s management remains focused on strengthening its financial position and exploring growth opportunities through its AmorphOX drug delivery platform and pipeline products. Looking ahead, Orexo aims to stabilize its business operations and drive value through its opioid use disorder products and ongoing product development initiatives.